Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

Description

The Global Non-Hodgkin Lymphoma Market, valued at USD 7.24 Billion in 2024, is projected to experience a CAGR of 7.72% to reach USD 11.31 Billion by 2030. The global Non-Hodgkin Lymphoma market comprises a comprehensive array of diagnostic tools and therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies such as CAR T-cell therapy, radiation, and stem cell transplantation, tailored for various lymphoma subtypes. Market growth is primarily driven by the increasing global incidence of Non-Hodgkin Lymphoma and a rising preference for advanced treatment modalities like targeted therapies and immunotherapies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.24 Billion
Market Size 2030	USD 11.31 Billion
CAGR 2025-2030	7.72%
Fastest Growing Segment	T-cell Lymphoma
Largest Market	North America

Key Market Drivers

The Global Non-Hodgkin Lymphoma market is significantly propelled by sustained advancements in targeted therapies and immunotherapies, which offer enhanced treatment efficacy and improved patient outcomes. The continuous development of novel agents specifically designed to target molecular pathways implicated in lymphoma pathogenesis has expanded therapeutic options, particularly for patients with relapsed or refractory disease. For instance, according to Genmab, on June 26, 2024, the FDA approved epcoritamab-bysp, known as EPKINLY(R), for relapsed or refractory follicular lymphoma, representing the first and only T-cell engaging bispecific antibody administered subcutaneously for this indication. This progress not only provides new lifelines for patients but also fuels market expansion through the introduction of premium-priced, innovative treatments.

Key Market Challenges

The substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments, presents a significant impediment to the growth of the global Non-Hodgkin Lymphoma market. These high expenditures directly limit patient access to potentially life-saving interventions, especially in healthcare systems with constrained budgets or in regions lacking robust insurance frameworks.

Key Market Trends

The non-Hodgkin lymphoma market is significantly influenced by the accelerating shift towards personalized medicine, primarily propelled by advanced genomic profiling. This trend emphasizes tailoring treatments based on an individual patient's unique genetic makeup, leading to more targeted and effective therapeutic interventions. For instance, the European Hematology Association's (EHA) guidelines for large B-cell lymphomas and peripheral T-cell lymphomas in 2025 highlight the increasing cruciality of molecular profiling for accurate diagnosis and subtype identification, which directly informs personalized treatment strategies. The expedited delivery of such critical diagnostic information is further advanced, as exemplified by the FDA approval of Thermo Fisher Scientific's Oncomine Dx Express Test in September 2025, designed for companion diagnostics and tumor profiling with results available in as little as 24 hours. This capability enables faster and more precise treatment decisions, enhancing patient outcomes and driving market expansion for advanced diagnostic solutions.

Key Market Players

AbbVie Inc
Bristol-Myers Squibb Company
AstraZeneca plc
Johnson & Johnson Services, Inc.
Novartis AG
Seagen, Inc (Pfizer Inc.)
Bayer AG
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Merck & Co. Inc

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Hodgkin Lymphoma Market, By Disease Type:

B-cell Lymphomas
T-cell Lymphoma

Non-Hodgkin Lymphoma Market, By Drug Class:

Monoclonal Antibodies
Antibody-Drug Conjugates
BTK/BCL-2 Kinase Inhibitors
PI3 Kinase Inhibitors
Others

Non-Hodgkin Lymphoma Market, By Route of Administration:

Oral
Parenteral
Others

Non-Hodgkin Lymphoma Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Non-Hodgkin Lymphoma Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma Market.

Available Customizations:

Global Non-Hodgkin Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Hodgkin Lymphoma Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Disease Type (B-cell Lymphomas, T-cell Lymphoma)
- 5.2.2. By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Others)
- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. North America Non-Hodgkin Lymphoma Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Disease Type
- 6.2.2. By Drug Class
- 6.2.3. By Route of Administration
- 6.2.4. By Distribution Channel
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Non-Hodgkin Lymphoma Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Disease Type
    - 6.3.1.2.2. By Drug Class
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By Distribution Channel
- 6.3.2. Canada Non-Hodgkin Lymphoma Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Disease Type
    - 6.3.2.2.2. By Drug Class
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By Distribution Channel
- 6.3.3. Mexico Non-Hodgkin Lymphoma Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Disease Type
    - 6.3.3.2.2. By Drug Class
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By Distribution Channel

7. Europe Non-Hodgkin Lymphoma Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Disease Type
- 7.2.2. By Drug Class
- 7.2.3. By Route of Administration
- 7.2.4. By Distribution Channel
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Non-Hodgkin Lymphoma Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Disease Type
    - 7.3.1.2.2. By Drug Class
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By Distribution Channel
- 7.3.2. France Non-Hodgkin Lymphoma Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Disease Type
    - 7.3.2.2.2. By Drug Class
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By Distribution Channel
- 7.3.3. United Kingdom Non-Hodgkin Lymphoma Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Disease Type
    - 7.3.3.2.2. By Drug Class
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By Distribution Channel
- 7.3.4. Italy Non-Hodgkin Lymphoma Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Disease Type
    - 7.3.4.2.2. By Drug Class
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By Distribution Channel
- 7.3.5. Spain Non-Hodgkin Lymphoma Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Disease Type
    - 7.3.5.2.2. By Drug Class
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Non-Hodgkin Lymphoma Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Disease Type
- 8.2.2. By Drug Class
- 8.2.3. By Route of Administration
- 8.2.4. By Distribution Channel
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Non-Hodgkin Lymphoma Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Disease Type
    - 8.3.1.2.2. By Drug Class
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By Distribution Channel
- 8.3.2. India Non-Hodgkin Lymphoma Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Disease Type
    - 8.3.2.2.2. By Drug Class
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By Distribution Channel
- 8.3.3. Japan Non-Hodgkin Lymphoma Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Disease Type
    - 8.3.3.2.2. By Drug Class
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By Distribution Channel
- 8.3.4. South Korea Non-Hodgkin Lymphoma Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Disease Type
    - 8.3.4.2.2. By Drug Class
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By Distribution Channel
- 8.3.5. Australia Non-Hodgkin Lymphoma Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Disease Type
    - 8.3.5.2.2. By Drug Class
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Non-Hodgkin Lymphoma Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Disease Type
- 9.2.2. By Drug Class
- 9.2.3. By Route of Administration
- 9.2.4. By Distribution Channel
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Non-Hodgkin Lymphoma Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Disease Type
    - 9.3.1.2.2. By Drug Class
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By Distribution Channel
- 9.3.2. UAE Non-Hodgkin Lymphoma Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Disease Type
    - 9.3.2.2.2. By Drug Class
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By Distribution Channel
- 9.3.3. South Africa Non-Hodgkin Lymphoma Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Disease Type
    - 9.3.3.2.2. By Drug Class
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Disease Type
- 10.2.2. By Drug Class
- 10.2.3. By Route of Administration
- 10.2.4. By Distribution Channel
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Non-Hodgkin Lymphoma Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Disease Type
    - 10.3.1.2.2. By Drug Class
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By Distribution Channel
- 10.3.2. Colombia Non-Hodgkin Lymphoma Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Disease Type
    - 10.3.2.2.2. By Drug Class
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By Distribution Channel
- 10.3.3. Argentina Non-Hodgkin Lymphoma Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Disease Type
    - 10.3.3.2.2. By Drug Class
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Non-Hodgkin Lymphoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. AbbVie Inc
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Bristol-Myers Squibb Company
15.3. AstraZeneca plc
15.4. Johnson & Johnson Services, Inc.
15.5. Novartis AG
15.6. Seagen, Inc (Pfizer Inc.)
15.7. Bayer AG
15.8. F. Hoffmann-La Roche Ltd
15.9. Gilead Sciences Inc
15.10. Merck & Co. Inc